Law360, New York (September 25, 2012, 10:16 PM ET) -- A Massachusetts federal jury on Tuesday handed down a verdict in favor of a Johnson & Johnson unit sued by Abbott GmbH & Co. KG over a psoriasis treatment Abbott said infringed its antibody patents, finding claims in both patents invalid.
The jury nixed the human antibody two patents, clearing Johnson & Johnson subsidiary Janssen Biotech Inc. from infringement claims over its psoriasis treatment Stelara. It found claims in Abbott's U.S. Patent Numbers 6,914,128 and 7,504,485 invalid for obviousness and for not including written descriptions that...
Jury Finds For J&J Unit In Row Over Abbott Antibody Patents
To view the full article, take a free trial now.
